EDGAR Filing Documents for 0001104659-13-087209

Form 4 - Statement of changes in beneficial ownership of securities:

SEC Accession No. 0001104659-13-087209

Filing Date

2013-11-26

Accepted

2013-11-26 16:26:58

Documents

Period of Report

2013-11-26

Document Format Files

Seq	Description	Document	Type	Size
1	4	a4.html	4
1	4	a4.xml	4	3848
	Complete submission text file	0001104659-13-087209.txt		5250

Mailing Address C/O CALLISTO PHARMACEUTICALS, INC. 420 LEXINGTON AVENUE, SUITE 1609 NEW YORK NY 10170

Business Address

Type: 4 | Act: 34 | File No.: 000-55020 | Film No.: 131244505

Mailing Address 420 LEXINGTON AVENUE SUITE 2012 NEW YORK NY 10170

Business Address 420 LEXINGTON AVENUE SUITE 2012 NEW YORK NY 10170 212-297-0020

ContraVir Pharmaceuticals, Inc. (Issuer) CIK: 0001583771 (see all company filings)

IRS No.: 462783806 | State of Incorp.: DE | Fiscal Year End: 0630
SIC: 2834 Pharmaceutical Preparations